Janone inc. announces the issuance of u.s. patent covering a method of improving nerve function using jan101

Issuance of u.s. patent 11,247,902 b2 further bolsters janone inc.'s intellectual patent portfolio las vegas , june 7, 2022 /prnewswire/ -- janone inc. (nasdaq: jan), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that a patent was issued that covers a method of improving nerve function using jan101. jan101 (formerly known as tv1001sr), is a potential treatment for peripheral artery disease (pad), a vascular disease that affects more than 8.5 million people in the u.s. and more than 60 million people worldwide.
JAN Ratings Summary
JAN Quant Ranking